BioSpace News Archive

REGENXBIO Inc. announced it completed dosing across all five cohorts in the Phase I/IIa clinical trial of RGX-314 for the treatment of wet age-related macular degeneration.

Announces Additions of Dr. David N. Cook to Board of Directors and Dr. Boudewijn DeJonge to Leadership Team

Verastem, Inc. announced that the Company will present at the Jefferies 2019 Global Healthcare Conference on Friday, June 7, 2019 at 11:30 a.m. EDT in New York, NY.

ArQule, Inc. announced that Paolo Pucci, Chief Executive Officer, Peter Lawrence, President and Chief Operating Officer, and Marc Schegerin, Chief Financial Officer and Head of Strategy, will present at the Jefferies 2019 Healthcare Conference on June 6, 2019 at 11:30 a.m. ET at the Grand Hyatt in New York City.

Deciphera Pharmaceuticals, Inc. announced that Steve Hoerter, President and Chief Executive Officer, will present at the Jefferies Global Healthcare Conference on Thursday, June 6 at 1:30 PM ET in New York City.

Acerus Pharmaceuticals Corporation announced that it has signed a patent license agreement with the University of Texas at Austin for technology related to the nasal administration of testosterone.

F-star, a clinical-stage biopharmaceutical company delivering tetravalent bispecific antibodies for a paradigm-shift in cancer therapy, today provides a Phase 1 clinical update on its wholly-owned lead programme FS118 and announces a presentation at the ASCO Annual Meeting (Chicago, 01 June 2019).

T Biopharma, Inc. an immuno-oncology company focused on innovative treatments based on the Company’s proprietary NK cell engager (TriKE) platform and Multi-Target Directed Bispecific Drug Conjugate (MTBDC) platform, provided an update with respect to the further clinical development of GTB-1550.

KalVista Pharmaceuticals, Inc. announced that it will present at the Jefferies Healthcare Conference on Thursday, June 6, 2019, at 4:00 p.m. ET in New York, NY.

Allegheny Health Network announced a partnership with advance care planning technology provider, Vynca, to further assist patients and their families with end-of-life care decisions.